Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients' and professionals' expertise - a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative.

[1]  G. Rauch,et al.  1412OPHASE II STUDY EVALUATING IMATINIB TO INDUCE PROGRESSION ARREST IN RECIST PROGRESSIVE DESMOID TUMORS NOT AMENABLE TO SURGICAL RESECTION WITH R0 INTENT OR ACCOMPANIED BY UNACCEPTABLE FUNCTION LOSS - A STUDY OF THE GERMAN INTERDISCIPLINARY SARCOMA GROUP (GISG). , 2014, Annals of Oncology.

[2]  M. Bertagnolli,et al.  Desmoid-Type Fibromatosis and Pregnancy: A Multi-institutional Analysis of Recurrence and Obstetric Risk , 2014, Annals of surgery.

[3]  D. Biau,et al.  Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. , 2014, The Journal of bone and joint surgery. American volume.

[4]  C. Mussi,et al.  Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  S. Bonvalot,et al.  CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence , 2013, Cancer.

[6]  S. Gwyther,et al.  Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Bonvalot,et al.  Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought , 2013, Annals of Surgical Oncology.

[8]  Andrew,et al.  β-Catenin mutation status and outcomes in sporadic desmoid tumors. , 2013, The oncologist.

[9]  David W. Henry,et al.  Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study , 2013, Pediatric blood & cancer.

[10]  L. Strauss,et al.  Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib , 2013, BioMed research international.

[11]  J. Coindre,et al.  CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics , 2012, Modern Pathology.

[12]  Leyun Pan,et al.  Dynamic PET With FDG in Patients With Unresectable Aggressive Fibromatosis: Regression-Based Parametric Images and Correlation to the FDG Kinetics Based on a 2-Tissue Compartment Model , 2012, Clinical nuclear medicine.

[13]  Wei-Lien Wang,et al.  CTNNB1 Genotyping and APC Screening in Pediatric Desmoid Tumors: A Proposed Algorithm , 2012, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[14]  J. Blay,et al.  Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Hohenberger,et al.  Desmoid tumors: clinical features and treatment options for advanced disease. , 2011, The oncologist.

[16]  J. Blay,et al.  Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  L. Strauss,et al.  Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  C. Antonescu,et al.  Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis , 2010, Clinical Cancer Research.

[19]  J. Blay,et al.  High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management , 2010, British Journal of Cancer.

[20]  D. Kool,et al.  Predictors for the Selection of Patients for Abdominal CT After Blunt Trauma: A Proposal for a Diagnostic Algorithm , 2010, Annals of surgery.

[21]  L. Mariani,et al.  Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution: Local Control Directly Impacts Survival , 2010, Annals of surgery.

[22]  Patrick T. Liu,et al.  Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors , 2010, Skeletal Radiology.

[23]  Robin L. Jones,et al.  Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. , 2009, European journal of cancer.

[24]  P. Terrier,et al.  Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient , 2009, Annals of Surgical Oncology.

[25]  L. Mariani,et al.  Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment , 2009, Annals of Surgical Oncology.

[26]  S. Bonvalot,et al.  Can the MRI signal of aggressive fibromatosis be used to predict its behavior? , 2009, European journal of radiology.

[27]  A. Lazar,et al.  Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. , 2008, The American journal of pathology.

[28]  M. Ballo,et al.  Long-term outcomes for desmoid tumors treated with radiation therapy. , 2008, International journal of radiation oncology, biology, physics.

[29]  J. Blay,et al.  Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[30]  M. Ballo,et al.  Optimizing treatment of desmoid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Skapek,et al.  Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Fletcher,et al.  Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Ballo,et al.  Prognostic factors for patients with localized soft‐tissue sarcoma treated with conservation surgery and radiation therapy , 2003, Cancer.

[34]  L. Mariani,et al.  Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  G. Aravantinos,et al.  The pharmacological treatment of aggressive fibromatosis: a systematic review. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Axel Hoos,et al.  Analysis of the Prognostic Significance of Microscopic Margins in 2,084 Localized Primary Adult Soft Tissue Sarcomas , 2002, Annals of surgery.

[37]  C. Blomqvist,et al.  Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. , 2000, European journal of cancer.

[38]  D. Leung,et al.  The enigma of desmoid tumors. , 1999, Annals of surgery.

[39]  J. Blay,et al.  Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.